
Claims

1. A compound of the formula I, in any of its stereoisomeric forms, or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, ~~or a physiologically acceptable solvate of any of them,~~



I

wherein

A is chosen from NH, O and S;

R^1 is chosen from $(C_1\text{-}C_6)$-alkyl, $(C_2\text{-}C_6)$-alkenyl, $(C_2\text{-}C_6)$-alkynyl, $(C_3\text{-}C_7)$-cycloalkyl-C_tH_{2t}- and Het-C_tH_{2t}-, wherein t is chosen from 0, 1, 2 and 3;

R^2 is chosen from phenyl and a residue of an aromatic, 5-membered to 6-membered monocyclic heterocycle which comprises 1, 2 or 3 identical or different ring heteroatoms chosen from N, O and S, wherein one of the ring nitrogen atoms can carry a hydrogen atom or a substituent R^{21}, and wherein the phenyl and residue of an aromatic heterocycle are optionally substituted on one or more ring carbon atoms by identical or different substituents R^{22};

R^3 is chosen from $(C_1\text{-}C_6)$-alkyl, $(C_2\text{-}C_6)$-alkenyl, $(C_2\text{-}C_6)$-alkynyl, $(C_3\text{-}C_7)$-cycloalkyl-C_uH_{2u}- and Het-C_vH_{2v}-, wherein u and v are chosen from 1 and 2, or R^3 is a residue of a saturated or unsaturated, 3-membered to 10-membered, monocyclic or bicyclic ring which comprises 0, 1, 2, 3 or 4 identical or different ring heteroatoms chosen from N, O and S, wherein one or two of the ring nitrogen atoms can carry a hydrogen atom or a $(C_1\text{-}C_4)$-alkyl substituent and one or two of the ring sulfur atoms can carry

m is chosen from 0, 1 and 2, wherein all numbers m are independent of each other;

wherein all cycloalkyl groups, independently of each other and independently of any other substituents, are optionally substituted by one or more identical or different substituents chosen from fluorine and $(C_1$-$C_4)$-alkyl;

wherein all alkyl, C_tH_{2t}, C_uH_{2u}, C_vH_{2v}, C_wH_{2w}, alkenyl and alkynyl groups, independently of each other and independently of any other substituents, are optionally substituted by one or more fluorine substituents.

2. A compound of the formula I, in any of its stereoisomeric forms, or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, ~~or a physiologically acceptable solvate of any of them,~~ as claimed in claim 1, wherein R^1 is chosen from $(C_1$-$C_6)$-alkyl, $(C_3$-$C_7)$-cycloalkyl-C_tH_{2t}- and Het-C_tH_{2t}-, wherein t is chosen from 0, 1 and 2.

3. A compound of the formula I, in any of its stereoisomeric forms, or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, ~~or a physiologically acceptable solvate of any of them~~, as claimed in one or more of claims 1 and 2, wherein R^2 is chosen from phenyl and pyridinyl, wherein the ring nitrogen atom of the pyridinyl can carry an oxy substituent, and wherein the phenyl and the pyridinyl are optionally substituted on one or more ring carbon atoms by identical or different substituents R^{22}.

4. A compound of the formula I, in any of its stereoisomeric forms, or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, ~~or a physiologically acceptable solvate of any of them,~~ as claimed in one or more of claims 1 to 3, wherein R^3 is chosen from $(C_3$-$C_7)$-cycloalkyl-C_uH_{2u}- and Het-C_vH_{2v}-, wherein u and v are chosen from 1 and 2, or R^3 is a residue of a saturated or unsaturated, 3-membered to 10-membered, monocyclic or bicyclic ring which comprises 0, 1, 2, 3 or 4 identical or different ring heteroatoms chosen from N, O and S, wherein one or two of the ring nitrogen atoms can carry a hydrogen atom or a $(C_1$-

C_4)-alkyl substituent and one or two of the ring sulfur atoms can carry one or two oxo groups, and wherein the residue of a ring is optionally substituted on one or more ring carbon atoms by identical or different substituents R^{31}.

5. A compound of the formula I, in any of its stereoisomeric forms, or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, ~~or a physiologically acceptable solvate of any of them,~~ as claimed in one or more of claims 1 to 4, wherein

R^1 is chosen from (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl-C_tH_{2t}- and Het-C_tH_{2t}-, wherein t is chosen from 0, 1 and 2;

R^2 is chosen from phenyl and pyridinyl, wherein the ring nitrogen atom of the pyridinyl can carry an oxy substituent, and wherein the phenyl and the pyridinyl are optionally substituted on one or more ring carbon atoms by identical or different substituents R^{22};

R^3 is chosen from (C_3-C_7)-cycloalkyl-C_uH_{2u}- and Het-C_vH_{2v}-, wherein u and v are chosen from 1 and 2, or R^3 is a residue of a saturated or unsaturated, 3-membered to 10-membered, monocyclic or bicyclic ring which comprises 0, 1, 2, 3 or 4 identical or different ring heteroatoms chosen from N, O and S, wherein one or two of the ring nitrogen atoms can carry a hydrogen atom or a (C_1-C_4)-alkyl substituent and one or two of the ring sulfur atoms can carry one or two oxo groups, and wherein the residue of a ring is optionally substituted on one or more ring carbon atoms by identical or different substituents R^{31}.

6. A compound of the formula I, in any of its stereoisomeric forms, or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, ~~or a physiologically acceptable solvate of any of them,~~ as claimed in one or more of claims 1 to 5, wherein

A is chosen from NH, O and S;

R^1 is chosen from (C_1-C_6)-alkyl, (C_3-C_7)-cycloalkyl-C_tH_{2t}- and Het-C_tH_{2t}-, wherein t is chosen from 0, 1 and 2;

Het is a residue of a saturated, 4-membered to 7-membered, monocyclic heterocycle which comprises 1 or 2 identical or different ring heteroatoms chosen from N, O and S and which is bonded via a ring carbon atom, wherein the residue of a heterocycle is optionally substituted by one or more identical or different substituents chosen from fluorine and $(C_1$-$C_4)$-alkyl;


m is chosen from 0, 1 and 2, wherein all numbers m are independent of each other;

wherein all cycloalkyl groups, independently of each other and independently of any other substituents, are optionally substituted by one or more identical or different substituents chosen from fluorine and $(C_1$-$C_4)$-alkyl;

wherein all alkyl, C_tH_{2t}, C_uH_{2u} and C_vH_{2v} groups, independently of each other and independently of any other substituents, are optionally substituted by one or more fluorine substituents.

7. A compound of the formula I, in any of its stereoisomeric forms, or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, ~~or a physiologically acceptable solvate of any of them,~~ as claimed in one or more of claims 1 to 6, wherein A is O.

8. A process for the preparation of a compound of the formula I as claimed in any of claims 1 to 7, comprising reacting a compound of the formula II with a compound of the formula III,



wherein the groups A, R^1, R^2 and R^3 in the compounds of the formulae II and III are defined as in the compounds of the formula I and additionally functional groups can be present in protected form or in the form of a precursor group, and the group Alk is $(C_1$-$C_4)$-alkyl.

9. A pharmaceutical composition, comprising at least one compound of the formula I as claimed in any of claims 1 to 7 or a physiologically acceptable salt thereof, ~~or a physiologically acceptable solvate of any of them,~~ and a pharmaceutically acceptable carrier.

10. A compound of the formula I as claimed in any of claims 1 to 7 or a physiologically acceptable salt thereof, ~~or a physiologically acceptable solvate of any of them,~~ for use as a pharmaceutical.

11. Use of a compound of the formula I as claimed in any of claims 1 to 7 or a physiologically acceptable salt thereof, ~~or a physiologically acceptable solvate of any of them~~in the manufacture of a medicament for treatingwound healing disorders.

12. Use of a compound of the formula I as claimed in any of claims 1 to 7 or a physiologically acceptable salt thereof, ~~or a physiologically acceptable solvate of any of them~~ in the manufacture of a medicament for wound healing.

13. Use of a compound of the formula I as claimed in any of claims 1 to 7 or a physiologically acceptable salt thereof, ~~or a physiologically acceptable solvate of any of them~~ in the manufacture of a medicament for wound healing in diabetics.

14. Use of a compound of the formula I as claimed in any of claims 1 to 7 or a physiologically acceptable salt thereof, ~~or a physiologically acceptable solvate of any of them~~in the manufacture of a medicament for treating diabetic foot syndrome.